Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec SE    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • The share is getting closer to its long-term support in weekly data, at EUR 15.94, which offers good timing for buyers.
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the EUR 17.97 support.
  • Historically, the company has been releasing figures that are above expectations.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • Analysts covering the stock have recently lowered their earnings forecast.
Ratings chart
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalisation (M$)Investor Rating
EVOTEC SE8.81%3 162
-
IQVIA HOLDINGS INC33.61%29 805
LONZA GROUP34.43%25 750
INCYTE CORPORATION30.71%17 337
CELLTRION, INC.--.--%16 155
EXACT SCIENCES CORPORATION87.35%15 308
SEATTLE GENETICS, INC.39.78%12 953
IONIS PHARMACEUTICALS INC27.78%9 481
GALAPAGOS92.22%9 277
GALAPAGOS NV (ADR)87.68%9 277
ALNYLAM PHARMACEUTICALS, IN..10.67%8 715
ICON PLC21.64%8 389
SAGE THERAPEUTICS INC69.12%8 318
QIAGEN-0.06%7 797
BIO-TECHNE CORP33.26%7 304
CHARLES RIVER LABORATORIES ..12.77%6 229
More Results
Financials (EUR)
Sales 2019 420 M
EBIT 2019 63,0 M
Net income 2019 47,9 M
Finance 2019 36,2 M
Yield 2019 -
P/E ratio 2019 59,2x
P/E ratio 2020 44,8x
EV / Sales2019 6,65x
EV / Sales2020 5,60x
Capitalization 2 832 M
Upcoming event on EVOTEC SE
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating -
Growth (Revenue) -
Valuation -
Finances -
Profitability -
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes